GB0405787D0 - Low dose vaccines - Google Patents

Low dose vaccines

Info

Publication number
GB0405787D0
GB0405787D0 GBGB0405787.3A GB0405787A GB0405787D0 GB 0405787 D0 GB0405787 D0 GB 0405787D0 GB 0405787 A GB0405787 A GB 0405787A GB 0405787 D0 GB0405787 D0 GB 0405787D0
Authority
GB
United Kingdom
Prior art keywords
hib
low dose
conjugate
dose vaccines
protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0405787.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32117706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0405787(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron SRL filed Critical Chiron SRL
Priority to GBGB0405787.3A priority Critical patent/GB0405787D0/en
Publication of GB0405787D0 publication Critical patent/GB0405787D0/en
Priority to US10/593,007 priority patent/US20090208526A1/en
Priority to PCT/IB2005/000927 priority patent/WO2005089794A2/en
Priority to EP05727218A priority patent/EP1725258B1/en
Priority to SG200901653-6A priority patent/SG151253A1/en
Priority to DE602005023422T priority patent/DE602005023422D1/de
Priority to RU2006136212/15A priority patent/RU2435609C2/ru
Priority to AT05727218T priority patent/ATE480257T1/de
Priority to BRPI0508813A priority patent/BRPI0508813B8/pt
Priority to CN2010105870900A priority patent/CN102028944B/zh
Priority to JP2007503444A priority patent/JP4954056B2/ja
Priority to DK05727218.9T priority patent/DK1725258T3/da
Priority to CN2005800152906A priority patent/CN1968711B/zh
Priority to CA2559996A priority patent/CA2559996C/en
Priority to JP2008056997A priority patent/JP2008150397A/ja
Priority to US13/250,094 priority patent/US9259460B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
GBGB0405787.3A 2004-03-15 2004-03-15 Low dose vaccines Ceased GB0405787D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0405787.3A GB0405787D0 (en) 2004-03-15 2004-03-15 Low dose vaccines
CN2005800152906A CN1968711B (zh) 2004-03-15 2005-03-14 含有低剂量hib偶联物的组合疫苗
CA2559996A CA2559996C (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate
AT05727218T ATE480257T1 (de) 2004-03-15 2005-03-14 Kombinationsvakzine mit niedriger dosis eines hib-konjugats
BRPI0508813A BRPI0508813B8 (pt) 2004-03-15 2005-03-14 vacinas líquidas de combinação com baixa dose de conjugado de hib
EP05727218A EP1725258B1 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate
SG200901653-6A SG151253A1 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate
DE602005023422T DE602005023422D1 (de) 2004-03-15 2005-03-14 Konjugats
RU2006136212/15A RU2435609C2 (ru) 2004-03-15 2005-03-14 КОМБИНИРОВАННЫЕ ВАКЦИНЫ С НИЗКОЙ ДОЗОЙ КОНЪЮГАТА Hib
US10/593,007 US20090208526A1 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate
PCT/IB2005/000927 WO2005089794A2 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate
CN2010105870900A CN102028944B (zh) 2004-03-15 2005-03-14 含有低剂量hib偶联物的组合疫苗
JP2007503444A JP4954056B2 (ja) 2004-03-15 2005-03-14 低用量のＨｉｂ結合体との組合せワクチン
DK05727218.9T DK1725258T3 (da) 2004-03-15 2005-03-14 Kombinationsvacciner med lav dosis Hib-konjugat
JP2008056997A JP2008150397A (ja) 2004-03-15 2008-03-06 低用量のＨｉｂ結合体との組合せワクチン
US13/250,094 US9259460B2 (en) 2004-03-15 2011-09-30 Combination vaccines with low dose of Hib conjugate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0405787.3A GB0405787D0 (en) 2004-03-15 2004-03-15 Low dose vaccines

Publications (1)

Publication Number Publication Date
GB0405787D0 true GB0405787D0 (en) 2004-04-21

Family

ID=32117706

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0405787.3A Ceased GB0405787D0 (en) 2004-03-15 2004-03-15 Low dose vaccines

Country Status (13)

Country Link
US (2) US20090208526A1 (enExample)
EP (1) EP1725258B1 (enExample)
JP (2) JP4954056B2 (enExample)
CN (2) CN102028944B (enExample)
AT (1) ATE480257T1 (enExample)
BR (1) BRPI0508813B8 (enExample)
CA (1) CA2559996C (enExample)
DE (1) DE602005023422D1 (enExample)
DK (1) DK1725258T3 (enExample)
GB (1) GB0405787D0 (enExample)
RU (1) RU2435609C2 (enExample)
SG (1) SG151253A1 (enExample)
WO (1) WO2005089794A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100898845B1 (ko) * 2000-06-29 2009-05-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 다가 백신 조성물
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
KR101359953B1 (ko) 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
CN103585624A (zh) 2006-09-07 2014-02-19 葛兰素史密丝克莱恩生物有限公司 疫苗
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
WO2008149238A2 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
EP2457590B1 (en) * 2008-05-01 2014-12-24 Arecor Limited Protein formulation
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
NZ598654A (en) 2009-09-02 2014-05-30 Novartis Ag Immunogenic compositions including tlr activity modulators
BR112012014689B1 (pt) * 2009-12-16 2019-11-12 Serum Institute Of India Private Limited composição imunogênica
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
AU2012245198B2 (en) * 2011-04-21 2017-07-13 Trustees Of Tufts College Compositions and methods for stabilization of active agents
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
PL2911676T3 (pl) * 2012-10-29 2020-12-28 The Board Of Trustees Of The University Of Arkansas Nowe adiuwanty śluzówkowe oraz systemy dostarczania
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
JP7404226B2 (ja) 2017-07-18 2023-12-25 セラム インスティテュート オブ インディア プライベート リミティド 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス
CN110251667A (zh) * 2018-05-11 2019-09-20 武汉博沃生物科技有限公司 一种免疫组合制剂及其制备方法和应用
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN118903397A (zh) * 2024-10-12 2024-11-08 成都迈科康生物科技有限公司 GloboH六糖、linker化合物、蛋白偶联物及免疫原性组合物在治疗或抑制上皮性肿瘤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
EP0833662B2 (en) * 1995-06-23 2011-01-26 SmithKline Beecham Biologicals S.A. A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate
KR100898845B1 (ko) * 2000-06-29 2009-05-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 다가 백신 조성물

Also Published As

Publication number Publication date
CN1968711B (zh) 2011-01-05
DK1725258T3 (da) 2010-11-01
EP1725258B1 (en) 2010-09-08
CA2559996C (en) 2014-08-05
CA2559996A1 (en) 2005-09-29
BRPI0508813B1 (pt) 2019-05-21
ATE480257T1 (de) 2010-09-15
US20120107346A1 (en) 2012-05-03
JP4954056B2 (ja) 2012-06-13
CN102028944A (zh) 2011-04-27
CN1968711A (zh) 2007-05-23
JP2007529503A (ja) 2007-10-25
BRPI0508813B8 (pt) 2021-05-25
SG151253A1 (en) 2009-04-30
US20090208526A1 (en) 2009-08-20
CN102028944B (zh) 2013-12-04
US9259460B2 (en) 2016-02-16
RU2006136212A (ru) 2008-04-27
DE602005023422D1 (de) 2010-10-21
JP2008150397A (ja) 2008-07-03
WO2005089794A2 (en) 2005-09-29
EP1725258A2 (en) 2006-11-29
BRPI0508813A (pt) 2007-08-07
RU2435609C2 (ru) 2011-12-10
WO2005089794A3 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
GB0405787D0 (en) Low dose vaccines
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
UY26801A1 (es) Composición de vacuna
GB0500787D0 (en) Integration of meningococcal conjugate vaccination
IL145982A0 (en) Vaccines
PE11298A1 (es) Vacunas
CY1111814T1 (el) Ενσωματωση του εμβολιασμου μηνιγγιτιδοκοκκικων συζευματων
MY148141A (en) Vaccine
IL107387A (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
WO2005007804A3 (en) Anthrax conjugate vaccine and antibodies
AU2001269569A1 (en) Quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis surface antigen, and preparation method thereof
MY127452A (en) Vaccines.
CA2366316A1 (en) Multi-component vaccine comprising at least three antigens to protect against disease caused by haemophilus influenzae
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
Bae et al. Quadrivalent combined vaccine, including diphtheria toxoid, tetanus toxoid, detoxified whole cell pertussis, and hepatitis B surface antigen
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)